gvhdhub.scientificeducationsupport.com Open in urlscan Pro
206.189.247.86  Public Scan

Form analysis
2 forms found in the DOM

<form class="sc-eNQAEJ jnosnH">
  <div width="100%" class="sc-bdVaJa fwHnPy"><input placeholder="Search something..." class="sc-hMqMXs jMdlTS" value="">
    <div class="sc-bdVaJa ctaqHx"><button type="submit" color="primary.base" font-size="1.3rem" height="40px" width="55px" class="sc-EHOje ffaYkm"><span class="sc-bxivhb ckHtGy"><svg aria-hidden="true" focusable="false" data-prefix="far"
            data-icon="search" class="svg-inline--fa fa-search fa-w-16 " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512">
            <path fill="currentColor"
              d="M508.5 468.9L387.1 347.5c-2.3-2.3-5.3-3.5-8.5-3.5h-13.2c31.5-36.5 50.6-84 50.6-136C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c52 0 99.5-19.1 136-50.6v13.2c0 3.2 1.3 6.2 3.5 8.5l121.4 121.4c4.7 4.7 12.3 4.7 17 0l22.6-22.6c4.7-4.7 4.7-12.3 0-17zM208 368c-88.4 0-160-71.6-160-160S119.6 48 208 48s160 71.6 160 160-71.6 160-160 160z">
            </path>
          </svg></span></button></div>
  </div><button color="white" font-size="1.8rem" height="40px" width="38px" class="sc-EHOje bwZRDk"><span class="sc-bxivhb ckHtGy"><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="times" class="svg-inline--fa fa-times fa-w-10 "
        role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512">
        <path fill="currentColor"
          d="M207.6 256l107.72-107.72c6.23-6.23 6.23-16.34 0-22.58l-25.03-25.03c-6.23-6.23-16.34-6.23-22.58 0L160 208.4 52.28 100.68c-6.23-6.23-16.34-6.23-22.58 0L4.68 125.7c-6.23 6.23-6.23 16.34 0 22.58L112.4 256 4.68 363.72c-6.23 6.23-6.23 16.34 0 22.58l25.03 25.03c6.23 6.23 16.34 6.23 22.58 0L160 303.6l107.72 107.72c6.23 6.23 16.34 6.23 22.58 0l25.03-25.03c6.23-6.23 6.23-16.34 0-22.58L207.6 256z">
        </path>
      </svg></span></button>
</form>

<form class="sc-eNQAEJ jnosnH">
  <div width="100%" class="sc-bdVaJa fwHnPy"><input placeholder="Search something..." class="sc-hMqMXs jMdlTS" value="">
    <div class="sc-bdVaJa ctaqHx"><button type="submit" color="primary.base" font-size="1.3rem" height="40px" width="55px" class="sc-EHOje ffaYkm"><span class="sc-bxivhb ckHtGy"><svg aria-hidden="true" focusable="false" data-prefix="far"
            data-icon="search" class="svg-inline--fa fa-search fa-w-16 " role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512">
            <path fill="currentColor"
              d="M508.5 468.9L387.1 347.5c-2.3-2.3-5.3-3.5-8.5-3.5h-13.2c31.5-36.5 50.6-84 50.6-136C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c52 0 99.5-19.1 136-50.6v13.2c0 3.2 1.3 6.2 3.5 8.5l121.4 121.4c4.7 4.7 12.3 4.7 17 0l22.6-22.6c4.7-4.7 4.7-12.3 0-17zM208 368c-88.4 0-160-71.6-160-160S119.6 48 208 48s160 71.6 160 160-71.6 160-160 160z">
            </path>
          </svg></span></button></div>
  </div><button color="white" font-size="1.8rem" height="40px" width="38px" class="sc-EHOje bwZRDk"><span class="sc-bxivhb ckHtGy"><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="times" class="svg-inline--fa fa-times fa-w-10 "
        role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 320 512">
        <path fill="currentColor"
          d="M207.6 256l107.72-107.72c6.23-6.23 6.23-16.34 0-22.58l-25.03-25.03c-6.23-6.23-16.34-6.23-22.58 0L160 208.4 52.28 100.68c-6.23-6.23-16.34-6.23-22.58 0L4.68 125.7c-6.23 6.23-6.23 16.34 0 22.58L112.4 256 4.68 363.72c-6.23 6.23-6.23 16.34 0 22.58l25.03 25.03c6.23 6.23 16.34 6.23 22.58 0L160 303.6l107.72 107.72c6.23 6.23 16.34 6.23 22.58 0l25.03-25.03c6.23-6.23 6.23-16.34 0-22.58L207.6 256z">
        </path>
      </svg></span></button>
</form>

Text Content

You need to enable JavaScript to run this app.

All content on this site is intended for healthcare professionals only. By
acknowledging this message and accessing the information on this website you are
confirming that you are a Healthcare Professional.

THE GVHD HUB USES COOKIES ON THIS WEBSITE. THEY HELP US GIVE YOU THE BEST ONLINE
EXPERIENCE. BY CONTINUING TO USE OUR WEBSITE WITHOUT CHANGING YOUR COOKIE
SETTINGS, YOU AGREE TO OUR USE OF COOKIES IN ACCORDANCE WITH OUR UPDATED COOKIE
POLICY

Yes, I accept cookies
  TRANSLATE


  Powered by Google Übersetzer

The GvHD Hub website uses a third-party service provided by Google that
dynamically translates web content. Translations are machine generated, so may
not be an exact or complete translation, and the GvHD Hub cannot guarantee the
accuracy of translated content. The GvHD Hub and its employees will not be
liable for any direct, indirect, or consequential damages (even if foreseeable)
resulting from use of the Google Translate feature. For further support with
Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

VISIT:

ALL Hub

AML Hub

Lupus Hub

Lymphoma Hub

MDS Hub

MPN Hub

Multiple Myeloma Hub



VIEW ALL CONTENT
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
VIEW ALL

GVHD TYPES

Acute graft-versus-host disease
Chronic graft-versus-host disease
Graft-versus-host disease
Risk
View all Types

VIEW ALL CONTENT


ASH 2022 ABSTRACTS: WHAT’S HOT IN GVHD?

To help navigate the exciting content being presented at ASH 2022, the GvHD Hub
Steering Committee have provided their recommendations for the top abstracts to
look out for in GvHD.

NOV 29, 2022

|ASH 2022

Does using haplo-HSCT compared with cord blood transplant impact GvHD rates?

The GvHD Hub was pleased to speak to Takanori Teshima. We asked, Does using
haploidentical hematopoietic stem cell transplantation compared with cord blood
transplant impact...

NOV 10, 2022

|GVHD

The safety and efficacy of fecal microbiota therapy in patients with GvHD

Here, we discuss a systemic review of 23 clinical trials, studies, and case
reports of FMT in patients with acute or chronic GvHD by Bilinski et al.
published in Bone Marrow...

NOV 7, 2022

|GI AGVHD

Editorial theme | Nutritional support for improved clinical outcomes post HSCT

For the first piece in this editorial theme, we are pleased to present a summary
of the role and effect of nutrition on clinical outcomes in patients undergoing
HSCT.

NOV 2, 2022

|GVHD

MOHAMAD MOHTY

"The new GvHD Hub is an amazing resource for physicians and healthcare
professionals in the field of GvHD. We have recently seen some great advances in
this era, and the GvHD Hub is the place to go for the most up-to-date
information."



MOHAMAD MOHTY

"The new GvHD Hub is an amazing resource for physicians and healthcare
professionals in the field of GvHD. We have recently seen some great advances in
this era, and the GvHD Hub is the place to go for the most up-to-date
information."



Featured Expert Opinion

What is the latest update on biomarkers for assessing GvHD?

During the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
(Tandem Meetings), the GvHD Hub was...



Are you a healthcare professional? What is your specialty?

Your specialty

Your specialty

Please select or type your specialty

Submit

×

By sharing this information, you can help ensure we continue to develop content
that is of most relevance for our audience.

Thank you for submitting.

STEROID-REFRACTORY GVHD

view more

ASH 2022 abstracts: What’s hot in GvHD?

To help navigate the exciting content being presented at ASH 2022, the GvHD Hub
Steering Committee have provided their recommendations for the top abstracts
to...

NOV 29, 2022

|ASH 2022

The safety and efficacy of low-dose interleukin-2 for the treatment of SR-cGvHD

Here, we discuss the combined results of five phase I or II clinical trials
(NCT00529035, NCT01366092, NCT01937468,...

SEP 30, 2022

|SR GVHD

How should novel agents be used in the current treatment pathways for GvHD?

During the GvHD Hub Steering Committee meeting on April 5, 2022, key opinion
leaders met to debate the question of how novel...

JUL 20, 2022

Abatacept as a novel agent for the treatment of steroid-refractory cGvHD: A
phase II trial

The results of a phase II clinical trial of abatacept for steroid-refractory
chronic graft-versus-host...

JUN 13, 2022

|TCT 2022

PEDIATRIC GVHD

view more

Findings from the prospective iMAGINE trial of ibrutinib in pediatric patients
with chronic GvHD

Chronic graft-versus-host disease (cGvHD) is a significant cause of mortality
and morbidity after...

MAY 30, 2022

|PEDIATRIC GVHD

Editorial theme | T-cell depletion strategies to reduce incidence of GvHD in
pediatric HSCT recipients

The current educational theme on the GvHD Hub explores the treatment of
pediatric...

MAY 3, 2022

|PEDIATRIC GVHD

How does GvHD affect outcomes for pediatric patients undergoing allo-SCT for
ALL?

During the 48th Annual Meeting of the European Society for Blood and Marrow
Transplantation (EBMT), the ALL Hub spoke...

APR 7, 2022

|EBMT 2022

Editorial theme | Genetic predisposition and endoscopic diagnosis of aGvHD in
pediatric patients

In this article, we summarize two publications; one on the genetic
susceptibility of pediatric patients...

MAR 31, 2022

|PEDIATRIC GVHD

MOST READ

Editorial theme | Nutritional support for improved clinical outcomes post HSCT

The safety and efficacy of fecal microbiota therapy in patients with GvHD

ASH 2022 abstracts: What’s hot in GvHD?

IRENE-G: A prospective RCT of nutritional support following allo-HSCT

CONGRESSES

view more

ASH 2022 abstracts: What’s hot in GvHD?

To help navigate the exciting content being presented at ASH 2022, the GvHD Hub
Steering Committee have provided their recommendations for the top abstracts
to...

NOV 29, 2022

|ASH 2022

Updated guidelines for post-HSCT vaccination

At the 5th Annual Meeting of the IACH, Ljungman presented the updated vaccine
guidelines for posttransplant patients. Here we summarize this presentation.

OCT 18, 2022

|IACH 2022

Patient and physician perceptions of palliative care during transplant

Here, we summarize two studies from the perspective of patient’s experiences
with palliative care. In addition, we summarize a...

OCT 13, 2022

|SOHO 2022

Updated results from a phase Ib and phase I/II trial of Orca-T

During the 27th Congress of the European Hematology Association (EHA2022),
Caspian Oliai presented updated results of a multicenter phase...

AUG 8, 2022

|EHA 2022

MOST VIEWED

Does using haplo-HSCT compared with cord blood transplant impact GvHD rates?

Mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role
in cGvHD treatment

How should novel agents be used in the current treatment pathways for GvHD?

How should duration of response be defined?

Brought to you by



In partnership with



Thank you to the funders of the GvHD Hub. All content is developed independently
by SES in collaboration with an expert steering committee; funders are allowed
no direct influence on the content of the hub.

Silver

Silver

BMS has provided an educational grant at the Contributor level
Contributor


Interested in becoming a supporter? Please contact us.

Terms and ConditionsCookie PolicyPrivacy PolicyNewsletter

© 2022 GvHD Hub

All content on this site is intended for healthcare professionals only.


ORIGINALTEXT


Bessere Übersetzung vorschlagen

--------------------------------------------------------------------------------